UBS Starts Medivation (MDVN) at Neutral
Tweet Send to a FriendGet Alerts MDVN Hot Sheet
Price: $48.86 -1.91%
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade MDVN Now!
Earlier, UBS initiates coverage on Medivation (NASDAQ: MDVN) with a Neutral rating and $59 price target.
"We view Medivation as a high-quality mid-cap biotech, with lead asset Xtandi poised to become part of the standard of care in metastatic prostate cancer," the analyst comments. "We have a favorable long-term view on the Xtandi opportunity, and think it’s likely that future clinical trial data support differentiated claims vs. competing product Zytiga. However, we initiate with a Neutral rating given high expectations for peak sales ahead of key de-risking data (which implies significant downside risk, albeit less likely), and low likelihood of M&A until sales trends and key data are known."
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $55.35 yesterday, with a 52 week range of $43.16-$113.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"We view Medivation as a high-quality mid-cap biotech, with lead asset Xtandi poised to become part of the standard of care in metastatic prostate cancer," the analyst comments. "We have a favorable long-term view on the Xtandi opportunity, and think it’s likely that future clinical trial data support differentiated claims vs. competing product Zytiga. However, we initiate with a Neutral rating given high expectations for peak sales ahead of key de-risking data (which implies significant downside risk, albeit less likely), and low likelihood of M&A until sales trends and key data are known."
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $55.35 yesterday, with a 52 week range of $43.16-$113.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
- Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan
- Topeka Capital Starts Atmel (ATML) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
